Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 (previously presented): A method for preparing a stable, retroviral packaging cell line for generation of human serum-resistant retroviral vector particles (RVP) which comprises:

(a) introducing one or more packaging vectors into a fully human serum-resistant non-primate mammalian cell line, wherein said cell line exhibits no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe and is capable of producing fully human-serum-resistant RVP and wherein said vectors, either singly or collectively, express a cellular targeting protein and retroviral *gag* and *pol* genes in amounts sufficient to package said RVP; and

(b) recovering said packaging cell line.

Claims 2-3 (canceled)

Claim 4 (currently amended): The method of Claim 1 ~~or 42~~, wherein said cellular targeting protein is selected from a group consisting of an amphotropic retroviral retroviral *env* protein, a xenotropic retroviral *env* protein, a polytropic retroviral *env* protein, a JSRV *env* protein, vesicular stomatitis virus G protein or transferrin.

Claim 5 (currently amended): A packaging cell line produced by the method of ~~of~~ Claim 1 or ~~2~~ 4.

Claim 6 (currently amended): A method for preparing a stable, retroviral producer cell ~~cells~~ capable of producing human serum-resistant retroviral vector particles (RVP) which comprises

(a) introducing a retrovirus vector into the packaging cell line of Claim 1, wherein said retrovirus vector is capable of being packaged into an RVP and comprises a heterologous gene capable of expression in a human; and

(b) recovering said producer cells.

Claim 7 (canceled)

Claim 8 (previously presented): The method of Claim 6, wherein said cells are α-galactosyl positive.

Claim 9 (previously presented): The method of Claim 6, wherein said cellular targeting protein is an amphotropic retroviral *env* protein, a xenotropic retroviral *env* protein, a polytropic retroviral *env* protein, a JSRV *env* protein, vesicular stomatitis virus G protein or transferrin.

Claim 10 (currently amended): Producer cells prepared by the method of Claim 6 ~~or 43~~.

Claim 11 (previously presented): A method for preparing human serum-resistant retroviral vector particles (RVP) which comprises:

(a) introducing a retrovirus vector into the packaging cell line of Claim 1, wherein said retrovirus vector is capable of being packaged into an RVP and comprises a heterologous gene capable of expression in a human;

(b) culturing said cell line for a time and under conditions sufficient to produce said RVP; and

(c) recovering said RVP.

Claim 12 (canceled)

Claim 13 (previously presented): The method of Claim 11, wherein said cell line is α-galactosyl positive.

Claim 14 (currently amended): The method of Claim 11 ~~or 44~~, wherein said cellular targeting protein is an amphotropic retroviral *env* protein, a xenotropic retroviral *env* protein,

a polytropic retroviral *env* protein, a JSRV *env* protein, vesicular stomatitis virus G protein or transferrin.

Claim 15 (canceled)

Claim 16 (previously presented): A method for preparing human serum-resistant retroviral vector particles (RVP) which comprises:

(a) culturing the producer cells of Claim 6 for a time and under conditions sufficient to produce said RVP; and

(c) recovering said RVP.

Claim 17 (previously presented): The method of Claim 16, wherein said cells are α-galactosyl positive.

Claim 18 (previously presented): The method of Claim 16, wherein said cellular targeting protein is an amphotropic retroviral *env* protein, a xenotropic retroviral *env* protein, a polytropic retroviral *env* protein, a JSRV *env* protein, vesicular stomatitis virus G protein or transferrin.

Claims 19-45 (canceled)

Claim 46 (previously presented): A method for preparing a stable, retroviral packaging cell line for generation of human serum-resistant retroviral particles (RVP) which comprises

(a) introducing one or more packaging vectors into a non-primate mammalian cell that is human serum resistant in 100% human serum, wherein said vectors, either singly or collectively, express a cellular targeting protein and retroviral *gag* and *pol* genes in amounts sufficient to package said RVP; and

(b) recovering said packaging cell line.

Claim 47 (canceled)

Claim 48 (previously presented): The method of Claim 46, wherein said cell line exhibits no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe.

Claim 49 (currently amended): The method of Claim 46 ~~or 47~~, wherein said cellular targeting protein is an amphotropic retroviral *env* protein, a xenotropic retroviral *env* protein, a polytropic retroviral *env* protein, a JSRV *env* protein, vesicular stomatitis virus G protein or transferrin.

Claim 50 (currently amended): A packaging cell line produced by the method of Claim 46 ~~or 47~~.

Claim 51 (previously presented): A method for preparing stable, retroviral producer cells capable of producing human serum-resistant retroviral vector particles (RVP) which comprises

(a) introducing a retrovirus vector into the packaging cell line of Claim 46, wherein said retrovirus vector is capable of being packaged into an RVP and comprises a heterologous gene capable or expression in a human; and

(b) recovering said producer cells.

Claim 52 (canceled)

Claim 53 (previously presented): The method of Claim 51, wherein said cells exhibit no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe.

Claim 54 (previously presented): The method of Claim 51, wherein said cellular targeting protein is an amphotropic retroviral *env* protein, a xenotropic retroviral *env* protein, a polytropic retroviral *env* protein, a JSRV *env* protein, vesicular stomatitis virus G protein or transferrin.

Claim 55 (currently amended): Producer cells prepared by the method of Claim 51 ~~or 52~~.

Claim 56 (previously presented): A method for preparing human serum-resistant retroviral vector particles (RVP) which comprises:

(a) introducing a retrovirus vector into the packaging cell line of Claim 46, wherein said retrovirus vector is capable of being packaged into an RVP and comprises a heterologous gene capable of expression in a human;

(b) culturing said cell line for a time and under conditions sufficient to produce said RVP; and

(c) recovering said RVP.

Claim 57 (canceled)

Claim 58 (previously presented): The method of Claim 56, wherein said cell line exhibits no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe.

Claim 59 (currently amended): The method of Claim 56 ~~or 57~~, wherein said cellular targeting protein is an amphotropic retroviral *env* protein, a xenotropic retroviral *env* protein, a polytropic retroviral *env* protein, a JSRV *env* protein, vesicular stomatitis virus G protein or transferrin.

Claim 60 (canceled)

Claim 61 (previously presented): A method for preparing human serum-resistant retroviral vector particles (RVP) which comprises:

(a) culturing the producer cells of Claim 51 for a time and under conditions sufficient to produce said RVP; and

(b) recovering said RVP.

Claim 62 (canceled)

Claim 63 (previously presented): The method of Claim 61, wherein said cells exhibit no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe.

Claim 64 (previously presented): The method of Claim 61, wherein said cellular targeting protein is an amphotropic retroviral *env* protein, a xenotropic retroviral *env* protein, a polytropic retroviral *env* protein, a JSRV *env* protein, vesicular stomatitis virus G protein or transferrin.

Claims 65-70 (canceled)